Transposase-Enabled CLD: From Transfection To High Titer With Ease

Developing effective biotherapeutics hinges on selecting the right cell line and workflow. However, traditional expression systems often struggle to keep up with the demands of novel molecular formats, tighter timelines, and the need for scalable, regulatory-compliant solutions.

Dr. Séverine Fagète, Site Head and Vice President of Mammalian Cell Line Development at KBI Biopharma, introduces a transposase-based platform designed to overcome these challenges. This innovative approach, built on the well-established Selexis® SUREtechnology™ platform and CHO-M™ cell line, offers significant advantages.

Learning Objectives

• Discover the key benefits of transposase-based gene integration compared to traditional cell line development methods.

• Understand how the Selexis® transposase-enabled cell line supports high titers, rapid development, and stability across various molecule types.

• Explore how this advanced cell line development empowers the creation of complex therapeutic and emerging protein formats, including multispecific antibodies, Fc-fusion proteins, and more, all while ensuring analytical rigor and regulatory compliance for clinical progression.